uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intranasal insulin in Alzheimer's disease: food for thought
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.ORCID iD: 0000-0001-7112-0921
Department of Pharmacology, Physiology and Neuroscience, University of South Carolina, School of Medicine, Columbia, SC 29209, USA.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.ORCID iD: 000-0002-8911-4068
2018 (English)In: Neuropharmacology, ISSN 0028-3908, E-ISSN 1873-7064, Vol. 136, p. 196-201Article in journal (Refereed) Published
Abstract [en]

Accumulating evidence suggests that disrupted brain insulin signaling promotes the development and progression of Alzheimer's disease (AD), driving clinicians to target this circuitry. While both traditional and more modern antidiabetics show promise in combating insulin resistance, intranasal insulin appears to be the most efficient method of boosting brain insulin. Furthermore, intranasal delivery elegantly avoids adverse effects from peripheral insulin administration. However, there remain significant open questions regarding intranasal insulin's efficacy, safety, and potential as an adjunct or mono-therapy. Thus, this review aims to critically evaluate the present evidence and future potential of intranasal insulin as a meaningful treatment for AD.

Place, publisher, year, edition, pages
Elsevier, 2018. Vol. 136, p. 196-201
Keywords [en]
Alzheimer's disease, Brain insulin resistance, Cognition, Intranasal insulin, Neurodegeneration
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:uu:diva-342186DOI: 10.1016/j.neuropharm.2017.11.037ISI: 000440121600006PubMedID: 29180222OAI: oai:DiVA.org:uu-342186DiVA, id: diva2:1183856
Funder
Novo Nordisk, NNF14OC0009349The Swedish Brain Foundation, FO2016-0092Swedish Research Council, 2015-03100Available from: 2018-02-19 Created: 2018-02-19 Last updated: 2018-11-20Bibliographically approved

Open Access in DiVA

fulltext(531 kB)10 downloads
File information
File name FULLTEXT01.pdfFile size 531 kBChecksum SHA-512
d90d5bda7ebd00df4ea068785b5c60d3946d07eab15ab2cb556b225f468fb704cdc4bc5898569705c787f1fbfa665f6877293b5187acdb902fe52ae51912ea82
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Chapman, Colin DSchiöth, Helgi B.Benedict, Christian

Search in DiVA

By author/editor
Chapman, Colin DSchiöth, Helgi B.Benedict, Christian
By organisation
Functional Pharmacology
In the same journal
Neuropharmacology
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 10 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 14 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf